FDA Enforcement Part 2: The Failure Themes That Recur Across 439 Inspection Documents

TL;DR

I tagged 439 FDA compounding enforcement documents by failure theme. Four themes show up in more than 60 percent of them:

• Facility and equipment design
• Insanitary conditions
• Cleaning and disinfection
• Sterility assurance

They aren’t isolated, the typical document includes 8 themes!

Interestingly, recent documents list more themes each, which suggests investigators are writing more comprehensive reports. The sharpest jumps came from quality unit and SOP gaps, batch records, and complaint handling. Each roughly doubled between the 2019 to 2021 documents and those from 2023 onward.

Pick the last cleaning record your pharmacy completed. Can you show what was done, who owned it, and how you know the work is still being done?

Taking a Step Back: From One Letter to the Whole Set

Part 1 started with one Warning Letter and what Michigan Medicine built afterward. It's a story of learning from an inspection and coming back stronger.

This post takes a step back. I wanted to know which problems FDA investigators write down most often, and which ones tend to show up together.

What This Set Is

I collected 680 FDA compounding enforcement documents issued between 2016 and 2026. They cover 321 pharmacies and outsourcing facilities.

439 of them include details from inspections, and mostare Form 483s. The rest are mostly state referral letters and cover documents with no findings to tag.

I tagged each of the 439 by recurring theme. A document can carry many themes, and most do.

Two limits matter:

• Keyword matching catches what the document says, not what the pharmacy did.
• This set comes from available public records. It is not a national failure rate.

The Themes That Recur

Here is how often each theme appears, as a share of the 439 substantive documents.

At the top are the issues around the physical sterile environment: the room, the hood, the cleaning, the airflow.

The middle covers the structure that keeps that environment under control: monitoring, procedures, the quality unit, dating, and testing.

Near the bottom sit batch records and complaints. These records show what was made and what happened after it left the pharmacy. They also show how a pharmacy notices and responds to a problem with its product. That makes them a key indicator of organizational oversight.

The Themes Travel Together

This is the finding I would want a quality lead to see first.

Only 37 of the 422 documents that match any theme match just one. The median document matches 8.

I grouped seven themes into a core sterile-environment set:

• Facility and equipment design
• Insanitary conditions
• Cleaning and disinfection
• Sterility assurance
• Smoke studies and airflow
• Aseptic technique
• Environmental monitoring

Then I checked how often they show up together. 383 of the 422 documents flag at least one of the seven. Here is how many of the seven each of those 383 documents flags.

The bars climb as the count goes up. 276 of the 383 (72%) flag four or more, and 80 flag all seven. Only 32 flag just one.

In other words, when an investigator writes up one part of the sterile environment, they usually write up most of it.

Cleaning, certification, monitoring, and gowning are separate tasks on paper, but they protect the same product. The data can't say which control slipped first. It does say that a document describing one of these problems usually describes several.

To me this points to a system problem. It's an argument for running these controls as one connected program, not seven separate checklists.

What Changed After 2021

I compared documents dated 2019 through 2021 (217 documents) with documents dated 2023 onward (128 documents). I left 2022 out to keep a clean break between the two periods.

Almost every theme appears more often in the later documents. The median document matched 7 themes in the earlier period and 10 in the later one.

So the question is where the increase was largest. Five themes roughly doubled or came close, and two went the other way.

This reads as a shift in what investigators write down, not proof of a shift in what pharmacies do. The 2019 and 2020 documents include a large wave of shorter inspections. Later documents are fewer and each one covers more ground.

Either way, the direction is useful. Recent documents keep coming back to the same questions:

• Does anyone review the work?
• Are procedures followed?
• Is monitoring data acted on?
• Are investigations and complaints logged and followed up?

Form 483s Versus Untitled Letters

The 383 Form 483s and 38 Untitled Letters that match a theme read differently.

Not one Untitled Letter in the set flags a quality-unit or SOP problem.

A Form 483 lists what the investigator observed, item by item. An Untitled Letter is a shorter advisory letter that names the conditions FDA objects to.

The procedure and record findings live in the 483. If you want to know what your own inspection could look like, the 483 is the document to study.

What Transfers Beyond Sterile Compounding

The most common themes in this set are sterile-environment themes. If your pharmacy compounds nonsterile preparations or handles hazardous drugs, several rows still apply directly:

• Component and ingredient quality
• Beyond-use dating and stability
• Cleaning and disinfection
• Quality unit and SOPs
• Production and batch records
• Complaints and adverse events
• Hazardous drug handling

Requirements follow the level of compounding you do, not the size of your operation. A small nonsterile pharmacy still needs an owner and a record for each control that applies to it.

The operating question is the same at every level: who owns the control, and what record shows it is still working?

This is why using an established centralized system is essential.

What to Do With This

The table is not a ranking of what to fix first.

I would not build a remediation plan from it. I would use it to find where your program is thin.

1. Map the core themes. For each theme that applies to your operation, name the recurring task that controls it, the person who owns it, and the record that proves it happened.
2. Check the rising themes. Take quality-unit review, batch records, and complaints. Ask whether each has a defined owner and a review step, or whether it happens when someone remembers.
3. Test one record. Run the five-question record test from Part 1 on a single piece of evidence: what was expected, who owned it, when it occurred, what supports completion, and who reviewed it.

Next in the Series

Part 3 looks at the firms that appear more than once in the set, and what a second Form 483 tends to repeat from the first.

Sources and Scope

• FDA Enforcement Part 1: What Michigan Medicine Built After an FDA Warning Letter
• FDA Form 483 Frequently Asked Questions
• FDA Regulatory Procedures Manual, Chapter 4: Advisory Actions
• FDA Compounding: Information for States

Counts come from Pomio's parsed set of 680 FDA compounding enforcement documents (2016 through 2026). Themes were assigned by keyword matching and a document can carry several. Theme shares use the 439 documents with substantive text; overlap and period figures use the 422 that match at least one theme. Redacted text in the source documents lowers some counts. Percentages describe this set, not the compounding industry, and do not establish requirements for any 503A pharmacy, 503B outsourcing facility, or state-board inspection. This article is educational and is not legal advice.